Altaris to Acquire Simulations Plus in a $375 Million Cash Deal

Key Takeaways

• Altaris to buy Simulations Plus for $375 million cash.
• Deal values Simulations Plus at $18.50 per share, 13% premium.
• Acquisition multiples: 4.09× sales, 20.73× EBITDA.
• Simulations Plus will merge with Altaris portfolio company CCG.
• Closing expected in Q4 2026, pending regulatory approvals.

Pulse Analysis

Altaris has built a reputation for targeting niche healthcare assets that can be scaled through operational expertise and capital support. Managing more than $9 billion in equity, the firm’s latest move places it squarely in the burgeoning market for advanced drug‑discovery platforms. By paying a modest 13% premium, Altaris demonstrates disciplined valuation discipline while still offering shareholders an attractive cash exit. The cash‑only structure also reflects the firm’s confidence in the target’s cash‑flow generation and its ability to fund integration without diluting existing investors. The deal is slated to close in Q4 2026, after standard regulatory approvals.

Simulations Plus provides modeling tools such as GastroPlus, MonolixSuite, ADMET Predictor and DILIsym, used by pharmaceutical companies and regulators worldwide. The platforms speed pharmacokinetic and toxicology predictions, shortening development timelines and cutting late‑stage failures. Merging the business with Chemical Computing Group, another Altaris portfolio asset focused on molecular design software, creates a vertically integrated suite that can serve end‑to‑end drug design, from target identification to safety assessment. The combined entity can capture cross‑sell opportunities and drive higher recurring revenue. Regulators have already incorporated several of Simulations Plus’s models into guidance documents, underscoring their credibility.

Private‑equity interest in life‑science software has surged as AI and cloud‑based platforms become critical to reducing R&D costs. The $375 million transaction, priced at roughly 4× sales, reflects a market that values scalability and data‑driven insight over traditional licensing models. For investors, the deal offers a clear exit for Simulations Plus shareholders while positioning Altaris to benefit from synergistic cost savings and expanded addressable market. As the sector consolidates, the combined Altaris‑CCG‑Simulations Plus platform could set a new benchmark for integrated drug‑discovery solutions. Analysts expect the combined firm to command higher EBITDA multiples as subscription revenues grow.